platoseedplatoseed
Using protein coupling to build new therapies
Catena’s technology lets us attach any two proteins together using an enzyme and the native amino acids tyrosine and cysteine within target proteins. It is a true platform technology because it enables the joining of any two soluble proteins together with minimal engineering and without restrictions due to protein size or complexity. Our work has already been used to modify cancer specific antibodies, CRISPR proteins and even cell surfaces. Our ability to produce modular protein therapeutics in a fraction of the time allows for true library creation across the therapeutics spectrum from oncology, vaccines, inflammatory disease and beyond.
CatenaBio develops a protein conjugation platform that enables multi-payload antibody conjugates using a CysTyr conjugation system for therapeutic applications, aiming to improve stability, DAR flexibility, and payload variety for next-generation ADCs, with a focus on solid tumors. Their MPC platform seeks to enable dual or multiple payloads and site-specific attachment beyond current ADC capabilities.
CatenaBio’s CysTyr Conjugation Platform enables attachment of multiple payloads to the same antibody using a novel C-Y Bond between cysteine and tyrosine. This allows flexible drug-to-antibody ratios, attachment of payloads of any size and complexity, and reportedly greater stability with reduced off-target release, enabling the creation of Multi-Payload Conjugates for antibody-drug conjugates (ADCs).
Who it’s for: Pharmaceutical and biotech companies developing next-generation antibody-drug conjugates and multi-payload therapeutics, particularly in oncology (solid tumors) with high unmet needs.
Executive leadership appointments noted; research and preclinical focus in oncology; conference and poster activity indicating ongoing R&D and external engagement
CEO and Co-Founder at Catena Biosciences. Marco completed his Ph.D. at UC Berkeley jointly between the labs of Matt Francis and Jennifer Doudna. When not starting a company or doing science Marco likes to backpack, rock climb, kayak, and just about any activity that involves not being inside.
AI-designed Affinity Reagents
High quality mRNA for therapeutic application
